{"version":1,"type":"story","url":"https://digestai.news/story/isomorphic-labs-aims-to-design-cancer-drugs-with-ai-plans-human-trials","json":"https://digestai.news/story/isomorphic-labs-aims-to-design-cancer-drugs-with-ai-plans-human-trials.json","markdown":"https://digestai.news/story/isomorphic-labs-aims-to-design-cancer-drugs-with-ai-plans-human-trials.md","slug":"isomorphic-labs-aims-to-design-cancer-drugs-with-ai-plans-human-trials","headline":"Isomorphic Labs aims to design cancer drugs with AI, plans human trials soon","summary":"Google DeepMind spinoff Isomorphic Labs, led by CEO Demis Hassabis and President Max Jaderberg, is using its AlphaFold-derived drug design engine to develop novel cancer, immune, and inflammatory disease treatments. The company has research partnerships with Novartis, Johnson & Johnson, and Eli Lilly, and has built a clinical development team in Boston in preparation for human trials, though Jaderberg declined to provide a timeline. Isomorphic's approach aims to predict molecular interactions across the entire body to minimize side effects and reduce the 90% failure rate typical in drug development. Competitors OpenAI and Anthropic have recently entered the space: OpenAI launched GPT‑Rosalind and acquired Orchestra Bio, while Anthropic partnered with six life sciences groups and targets human trials by late 2028. Experts including Oxford's Lennard Lee and Charlotte Deane caution that biological complexity remains a fundamental hurdle, and AI predictions often fail in living systems. Jaderberg emphasizes Isomorphic's focus on making medicines rather than licensing software, and sees its mission-driven culture as a hiring advantage amid safety-related departures at rival labs.","keyPoints":["Isomorphic Labs uses AlphaFold-based engine to design novel cancer and immune drugs","Partnerships with Novartis, Johnson & Johnson, Eli Lilly; clinical team built in Boston","OpenAI and Anthropic now competing with own drug discovery models and partnerships"],"whyItMatters":"AI-designed drugs have yet to reach patients; Isomorphic's progress toward human trials will test whether deep-learning protein models can overcome biology's complexity and the industry's 90% failure rate.","category":{"slug":"research","name":"Research","url":"https://digestai.news/category/research"},"entities":{"companies":["Isomorphic Labs","Google DeepMind","Novartis","Johnson & Johnson","Eli Lilly","OpenAI"],"models":["AlphaFold","GPT‑Rosalind"],"people":["Demis Hassabis","Max Jaderberg","Dario Amodei","Emilia Javorsky","Lennard Lee","Charlotte Deane"]},"firstPublishedAt":"2026-10-30T14:05:00Z","updatedAt":"2026-10-30T14:05:00Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"businessinsider.com","title":"Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs","url":"https://businessinsider.com/isomorphic-labs-discover-cancer-beating-drugs-ai-max-jaderberg-google-2026-10","publishedAt":"2026-10-30T14:05:00Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":{"title":"AI Biotech Expands Beyond Protein Folding Limits","url":"https://digestai.news/thread/deepmind-and-biohub-debate-alphafolds-limits-in-protein-folding","storyCount":3},"cite":{"text":"Digest AI, \"Isomorphic Labs aims to design cancer drugs with AI, plans human trials soon\", 30 October 2026, https://digestai.news/story/isomorphic-labs-aims-to-design-cancer-drugs-with-ai-plans-human-trials","publisher":"Digest AI","title":"Isomorphic Labs aims to design cancer drugs with AI, plans human trials soon","datePublished":"2026-10-30T14:05:00Z","url":"https://digestai.news/story/isomorphic-labs-aims-to-design-cancer-drugs-with-ai-plans-human-trials"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}